Cargando…

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing

Introduction: Optimal initial antithyroid drugs (ATD) dosing may achieve rapid improvement in thyroid hormone levels while minimizing risk of adverse events. As ATD have become the most common first line therapy for the treatment of Graves’ disease (GD), we examined trends over time in initial ATD d...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Kawkgi, Omar M, Vallejo, Sebastian, Li, Dingfeng, Lincango, Eddy, Mohan, Sneha, Kohlenberg, Jacob, Giblon, Rachel, Stan, Marius, Brito, Juan P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090277/ http://dx.doi.org/10.1210/jendso/bvab048.1690

Ejemplares similares

SAT-423 Anti-thyroid Drug Response in Graves’ Disease: Predictors of Biochemically Persistent Disease
por: El Kawkgi, Omar M, et al.
Publicado: (2020)

MON-589 Prognostic Predictors of Initial Response of Graves' Disease to Antithyroid Drugs: A Single Center Experience
por: Alaghoury, Aliaa, et al.
Publicado: (2019)

MON-621 A Second Course of Antithyroid Drug Therapy Is Effective in Patients with Relapsed Graves' Disease
por: Seejore, Khyatisha, et al.
Publicado: (2019)

THU670 Serum TSI Concentration In Patients With Graves’ Disease Undergoing Maintenance-dose Of Antithyroid Drug (ATD) And Its Relationship With Disease Relapse After ATD Withdrawal
por: Nhat Nguyen, Phong Vu, et al.
Publicado: (2023)

THU671 Genes Encoding Adaptive Immune Receptor Repertoire Might Be Associated With The Risk Of Graves’ Disease And Antithyroid Drug-induced Agranulocytosis
por: Jui Huang, Chun, et al.
Publicado: (2023)

A Grave Initial Presentation of Graves’ Disease in a Patient With Moyamoya
por: Clutter, Courtney, et al.
Publicado: (2021)

PSAT294 Black Thyroid – Is It a Benign or a Malignant Finding?: A Case Report and Review of the Literature
por: Cordero-Garate, Juana, et al.
Publicado: (2022)

SUN-515 Use of Plasmapheresis for Treatment of Thyroid Storm Resistant to Antithyroidals
por: Vega, Myrian Noella Vinan, et al.
Publicado: (2020)

PSAT323 Ultrasound-guided Percutaneous Ethanol Ablation for the treatment of Benign Cystic Thyroid Nodules: Report of Three Cases on The Initial Ecuadorian Experience
por: Naranjo, Eddy P Lincango, et al.
Publicado: (2022)

MON-550 Have New ATA Guidelines Changed the Diagnosis and Management of Thyroid Cancer? A Population-Based Study
por: Genere, Natalia, et al.
Publicado: (2019)

SAT-424 Assessing Content Validity of the Graves’ Ophthalmopathy Quality of Life Questionnaire (GO-QOL) in the United States
por: Stan, Marius N, et al.
Publicado: (2020)

MON-546 Drivers of Thyroid Cancer Diagnosis in a Middle-Income Country: An Analysis in a Thyroid Cancer Referral Center in Ecuador
por: Lincango Naranjo, Eddy, et al.
Publicado: (2019)

The Thionamide Paradox: Thyrotoxicosis With Neutropenia as Initial Presentation of Grave’s Disease
por: Celis, Valentina, et al.
Publicado: (2021)

SAT495 Persistent Euthyroid State in a Patient with Biochemical and Imaging Evidence of Graves' Disease
por: Antony, Mc Anto, et al.
Publicado: (2023)

SUN-424 Treatment of Antithyroid Drug-Induced Agranulocytosis with Granulocyte Colony-Stimulating Factor: A Meta-Analysis
por: Santos, Maria Regina C, et al.
Publicado: (2020)

Presentation and Outcome of Severe Graves’ Disease
por: Babu, Priya Mohan, et al.
Publicado: (2021)

OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves’ Hyperthyroidism
por: Kahaly, George, et al.
Publicado: (2019)

SAT-606 Graves' Orbitopathy Treated with Kahaly's Protocol: IV High Dose Glucocorticoids
por: Patel, Bijal, et al.
Publicado: (2019)

MON-567 Is Over Diagnosis Of Thyroid Cancer In A Non-high-income Country Impacting The Outcome Of Thyroid Cancer Surgery. An Assessment Of Surgical Outcomes In A Thyroid Cancer Referral Center In Ecuador
por: Solis Pazmiño, Andrea, et al.
Publicado: (2019)

SAT-415 Clinical Performance of Thyroid-Stimulating Immunoglobulin for Graves′ Disease Diagnosis
por: Marui, Suemi, et al.
Publicado: (2020)

Graves Disease in Infancy
por: Beliard, Kara A, et al.
Publicado: (2021)

RF11 | PSAT249 Radiofrequency Ablation for Thyroid Nodules: The First Ecuadorian Prospective Cohort
por: Naranjo, Eddy P Lincango, et al.
Publicado: (2022)

SUN-577 A Remarkable Case of Thyrotoxicosis Initially Caused by Graves' Disease Followed by a TSHoma
por: Quinn, Mark, et al.
Publicado: (2019)

Profound Hypothyroidism 21 Days After Methimazole Initiation in a Patient With Graves’s Disease and Liver Cirrhosis
por: Hammami, Safa, et al.
Publicado: (2021)

Effectiveness of Different Thyroid Stimulating Hormone Thresholds for Thyroid Hormone Withdrawal - Aided Radioiodine Ablation in Patients With Differentiated Thyroid Cancer: A Systematic Review and Meta - Analysis
por: Rojas, Tatiana, et al.
Publicado: (2021)

SUN-432 Utilizing Patient Online Forums to Capture Experiences and Perceptions Associated with the Use of Desiccated Thyroid Extract
por: Bonilla, Freddy J K Toloza, et al.
Publicado: (2020)

PSAT358 Graves’ Disease Complicated by Post-Operative Graves’ Ophthalmopathy and Pretibial Myxedema
por: Bowens, Brendan, et al.
Publicado: (2022)

SAT-625 Dose-Dependent, Methimazole-Induced Agranulocytosis in a Pregnant Hispanic Woman with Grave's Disease
por: Bello, Fatimah, et al.
Publicado: (2019)

ODP574 Characteristics of Grave's Disease Among Children and Adolescents in KSA
por: Alradadi, Rasha, et al.
Publicado: (2022)

THU665 Unilateral Graves’ Disease In A Bilobar Thyroid Gland: Unusual Cause Of Hyperthyroidism
por: Hamid Alaybaa, Khaled, et al.
Publicado: (2023)

SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
por: Rapier, Brandon, et al.
Publicado: (2020)

The Grave Hematologic and Hepatic Effects of Hyperthyroidism
por: Ahmad, Sara Miriam, et al.
Publicado: (2021)

An Unusual Etiology of Graves’ Disease: Alemtuzumab
por: Santiago Carrion, Ada Marie, et al.
Publicado: (2021)

Graves’ Disease Induced Severe Hypercalcemia
por: Lugo Lopez, Zahira Marie, et al.
Publicado: (2021)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

ODP531 Worsening of pretibial myxedema following repeated doses of radioiodine treatment in a patient with hyperthyroid Graves’ disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2022)

A Grave Turn on Hashimoto’s Thyroiditis - A Case Series on Four Patients With Autoimmune Hypothyroidism that Converted to Grave’s Disease
por: Lee, Michelle N, et al.
Publicado: (2021)

PSAT243 Late Versus Early Administration of Radioiodine Therapy for Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis
por: Lincango Naranjo, Eddy P, et al.
Publicado: (2022)

SUN-621 Lessons from beyond the Graves'
por: Chai, Thora, et al.
Publicado: (2019)

SUN-567 Moyamoya and Autoimmune Graves' Disease
por: Elagi, Daniyah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_92jrvjofn759ek2u8co2kes0i3